Key result
Berberine inhibits LOX-1 and increases SR-BI expression in human macrophage foam cells.
Answers are grounded in this paper and cite their sources.
This study investigates the effects of beriberine on the expression of lectin-like ox-LDL receptor-1 (LOX-1), scavenger receptor A (SR-A), SR class B type I (SR-BI) and ATP-binding cassette transporter A1 (ABCA1) in human macrophage-derived foam cells induced by ox-LDL. Different concentrations of Berberine were co-cultured with THP-1 derived foam cells. The mRNA and protein expressions of LOX-1, SR-A, SR-BI and ABCA1 were determined by RT-PCR and Western blot analysis, respectively. Ox-LDL significantly increased the expression of LOX-1 and inhibited the expression of SR-BI in a dose- and time-dependent manner. Berberine significantly inhibited the effects of ox-LDL in a dose- and time-dependent manner. Moreover, ox-LDL significantly promoted ABCA1 expression. However, berberine had no effect on SR-A or ABCA1 expression. Berberine can inhibit the expression of LOX-1 and promote the expression of SR-BI in macrophage-derived foam cells. Therefore, berberine could be used to treat atherosclerotic diseases.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2010) studied Atherosclerotic diseases (human macrophage-derived foam cells induced by ox-LDL). Berberine vs. ox-LDL without berberine was evaluated on mRNA and protein expression of LOX-1, SR-A, SR-BI, and ABCA1. Berberine significantly inhibited ox-LDL-induced LOX-1 expression and promoted SR-BI expression in human macrophage-derived foam cells in a dose- and time-dependent manner.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: